Supernus Pharmaceuticals, Inc. Net Income 2010–2025
Supernus Pharmaceuticals, Inc. reported $-38.55M of net income for fiscal 2025. That was 152.2% lower than fiscal 2024. Compared with fiscal 2020, the change was -130.4%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $-38.55M | -5.4% | -152.2% |
| FY 2024 | $73.86M | 11.2% | +5512.8% |
| FY 2023 | $1.32M | 0.2% | -97.8% |
| FY 2022 | $60.71M | 9.1% | +13.6% |
| FY 2021 | $53.42M | 9.2% | -57.9% |
| FY 2020 | $126.95M | 24.4% | +12.3% |
| FY 2019 | $113.06M | 28.8% | +1.9% |
| FY 2018 | $110.99M | 27.1% | +93.8% |
| FY 2017 | $57.28M | 19.0% | -37.2% |
| FY 2016 | $91.22M | 42.4% | +554.2% |
| FY 2015 | $13.94M | 9.5% | +227.6% |
| FY 2014 | $-10.93M | -11.8% | +88.2% |
| FY 2013 | $-92.27M | -767.7% | -99.4% |
| FY 2012 | $-46.28M | -3127.3% | -186.0% |
| FY 2011 | $53.81M | 6701.7% | +239.9% |
| FY 2010 | $-38.46M | -36285.8% | — |
Source: Supernus Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open SUPN 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Supernus Pharmaceuticals, Inc. reported $-38.55M of net income for fiscal 2025. That was 152.2% lower than fiscal 2024. Compared with fiscal 2020, the change was -130.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Supernus Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeSupernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s net income?
Supernus Pharmaceuticals, Inc. (SUPN) reported net income of $-38.55M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.